First, the experimental animals had no underlying disease, which is not consistent with the high-risk populations for cardiac arrest; second, CANA was administered at ROSC 15 min, which is not consistent with actual clinical administration; third, the CA + CANA + Nrf2 inhibitor group was not set up to verify the role of the Nrf2/HO-1 pathway; fourth, no corresponding cell experiments were performed; finally, the sample size of this study was relatively small. The gene discussed is HMOX1; the disease is cardiac arrest.